Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Published byปาริชาติ หงสกุล Modified over 5 years ago

Similar presentations

Presentation on theme: "Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,"— Presentation transcript:

1 Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo- Controlled Trial  Kim A. Papp, Cathy Reid, Peter Foley, Rod Sinclair, David H. Salinger, Gary Williams, Hua Dong, James G. Krueger, Chris B. Russell, David A. Martin  Journal of Investigative Dermatology  Volume 132, Issue 10, Pages (October 2012) DOI: /jid Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

2 Figure 1 Single doses of AMG 827 lead to rapid improvement in PASI responses. (a) Mean changes in PASI score from baseline. (b) Proportion of subjects achieving a PASI 50, PASI 75, and PASI 90 at any time during the study. IV, intravenously; PASI, Psoriasis Area and Severity Index; SD, standard deviation; SC, subcutaneously. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

3 Figure 2 Single doses of AMG 827 lead to rapid improvement in multiple skin biomarkers. (a) Epidermal thickness. Symbols in centers of box plots represent mean values, horizontal lines in centers of box plots represent median values, upper and lower edges of boxes represent 75th and 25th quartiles, respectively, and upper and lower error bars represent maximum and minimum values, respectively. P-values are for post-treatment level versus baseline. *P<0.001; †P<0.01; ‡P<0.05. (b) Hematoxylin and eosin stain to show epidermal thickness and immunohistochemistry staining for KRT16 and Ki67 messenger RNA (mRNA) levels in skin biopsies from a subject who received a single dose of 700mg IV AMG 827. Scale bar=0.1mm. (c) mRNA levels of keratinocyte-derived factors (upper panels) and inflammatory cytokines (lower panels). H&E, hematoxylin & eosin; IHC, immunohistochemistry; IV, intravenously; mRNA, messenger RNA; PL, placebo; SC, subcutaneously. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2012 The Society for Investigative Dermatology, Inc Terms and Conditions

Download ppt "Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,"

Similar presentations

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
1α,25-Dihydroxycholecalciferol and Cyclosporine Suppress Induction and Promote Resolution of Psoriasis in Human Skin Grafts Transplanted on to SCID Mice 

1α,25-Dihydroxycholecalciferol and Cyclosporine Suppress Induction and Promote Resolution of Psoriasis in Human Skin Grafts Transplanted on to SCID Mice 
Role of Angiogenic and Inflammatory Signal Pathways in Psoriasis

Role of Angiogenic and Inflammatory Signal Pathways in Psoriasis
Francesca Capon  Journal of Investigative Dermatology 

Francesca Capon  Journal of Investigative Dermatology 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,
Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights  Nicholas Gulati, Mayte Suárez-Fariñas,

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights  Nicholas Gulati, Mayte Suárez-Fariñas,
[Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers  Ross.

[Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers  Ross.
IL-27 Activates Th1-Mediated Responses in Imiquimod-Induced Psoriasis-Like Skin Lesions  Sayaka Shibata, Yayoi Tada, Yoshihide Asano, Koichi Yanaba, Makoto.

IL-27 Activates Th1-Mediated Responses in Imiquimod-Induced Psoriasis-Like Skin Lesions  Sayaka Shibata, Yayoi Tada, Yoshihide Asano, Koichi Yanaba, Makoto.
Dominant Th1 and Minimal Th17 Skewing in Discoid Lupus Revealed by Transcriptomic Comparison with Psoriasis  Ali Jabbari, Mayte Suárez-Fariñas, Judilyn.

Dominant Th1 and Minimal Th17 Skewing in Discoid Lupus Revealed by Transcriptomic Comparison with Psoriasis  Ali Jabbari, Mayte Suárez-Fariñas, Judilyn.
Nicole L. Ward, Narasimharao Bhagathavula, Andrew Johnston, Sean M

Nicole L. Ward, Narasimharao Bhagathavula, Andrew Johnston, Sean M
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis  Erin G. Harper, Changsheng Guo,

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis  Erin G. Harper, Changsheng Guo,
A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis  Catharine.

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis  Catharine.
Rolando Perez-Lorenzo, Kamraan Z. Gill, Che-Hung Shen, Feng X

Rolando Perez-Lorenzo, Kamraan Z. Gill, Che-Hung Shen, Feng X
Clinical Snippets Journal of Investigative Dermatology

Clinical Snippets Journal of Investigative Dermatology
IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions

IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions
IL-1R1 Signaling Facilitates Munro’s Microabscess Formation in Psoriasiform Imiquimod-Induced Skin Inflammation  Mireia Uribe-Herranz, Li-Hua Lian, Kirsten.

IL-1R1 Signaling Facilitates Munro’s Microabscess Formation in Psoriasiform Imiquimod-Induced Skin Inflammation  Mireia Uribe-Herranz, Li-Hua Lian, Kirsten.
Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin  Eve Maubec, Cédric Laouénan, Lydia Deschamps,

Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin  Eve Maubec, Cédric Laouénan, Lydia Deschamps,
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis  Kristian Reich,

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis  Kristian Reich,

Similar presentations

Ads by Google